While the extent of tumour cell PD-L1 expression is critical to treatment selection, in patients whose 1L treatments do not follow guidelines for PD-L1 expression, many clinical factors such as comorbidities, performance status, or contraindications are considered when making the treatment decision. Here, CD274 is linked to neoplasm.